Show simple item record

Variabilität des Therapieansprechens von Gemcitabin bei Pankreaskarzinom: Identifizierung relevanter Genpolymorphismen

Retrospektive Studie bei Patienten mit Pankreaskarzinom

dc.contributor.advisorBrockmöller, Jürgen Prof. Dr.de
dc.contributor.authorSchaudinn, Alexanderde
dc.date.accessioned2013-01-23T09:53:28Zde
dc.date.available2013-02-04T23:50:07Zde
dc.date.issued2013-01-23de
dc.identifier.urihttp://hdl.handle.net/11858/00-1735-0000-000D-F18A-Fde
dc.identifier.urihttp://dx.doi.org/10.53846/goediss-3369
dc.language.isodeude
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subject.ddc610de
dc.titleVariabilität des Therapieansprechens von Gemcitabin bei Pankreaskarzinom: Identifizierung relevanter Genpolymorphismende
dc.title.alternativeRetrospektive Studie bei Patienten mit Pankreaskarzinomde
dc.typedoctoralThesisde
dc.title.translatedVariability of therapy response in gemcitabine treated pancreatic carcinoma: Identifying relevant gene polymorphismsde
dc.contributor.refereeBrockmöller, Jürgen Prof. Dr.de
dc.date.examination2013-01-28de
dc.subject.gokKlinische Pharmakologiede
dc.description.abstractengGene polymophisms could play an important role in the variability of therapy response in gemcitabine treated patients with pancreatic carcinoma. The retrospective study showed that a polymorphism in ENT-1, a carrier of gemcitabine, had an influence on overall survival.de
dc.contributor.coRefereeLiersch, Torsten PD Dr.de
dc.title.alternativeTranslatedRetrospectiv study in patients with pancreatic carcinomade
dc.subject.engGemcitabinede
dc.subject.engGene Polymorphismde
dc.subject.engENT1de
dc.subject.engPancreatic Carcinomade
dc.identifier.urnurn:nbn:de:gbv:7-11858/00-1735-0000-000D-F18A-F-5de
dc.affiliation.instituteMedizinische Fakultätde
dc.description.embargoed2013-02-04de
dc.identifier.ppn737346035de


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record